Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer
Open Access
- 21 September 2011
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 399
Abstract
Background: P21(WAF1/Cip1) binds to cyclin-dependent kinase complexes and inhibits their activities. It was originally described as an inhibitor of cancer cell proliferation. However, many recent studies have shown that p21 promotes tumor progression when accumulated in the cell cytoplasm. So far, little is known about the correlation between cytoplasmic p21 and drug resistance. This study was aimed to investigate the role of p21 in the cisplatin resistance of ovarian cancer. Methods: RT-PCR, western blot and immunofluorescence were used to detect p21 expression and location in cisplatin-resistant ovarian cancer cell line C13* and its parental line OV2008. Regulation of cytoplasmic p21 was performed through transfection of p21 siRNA, Akt2 shRNA and Akt2 constitutively active vector in the two cell lines; their effects on cisplatin-induced apoptosis were evaluated by flow cytometry. Tumor tissue sections of clinical samples were analyzed by immunohistochemistry. Results: p21 predominantly localizes to the cytoplasm in C13* compared to OV2008. Persistent exposure to low dose cisplatin in OV2008 leads to p21 translocation from nuclear to cytoplasm, while it had not impact on p21 localization in C13*. Knockdown of cytoplasmic p21 by p21 siRNA transfection in C13* notably increased cisplatin-induced apoptosis through activation of caspase 3. Inhibition of p21 translocation into the cytoplasm by transfection of Akt2 shRNA into C13* cells significantly increased cisplatin-induced apoptosis, while induction of p21 translocation into the cytoplasm by transfection of constitutively active Akt2 in OV2008 enhanced the resistance to cisplatin. Immunohistochemical analysis of clinical ovarian tumor tissues demonstrated that cytoplasmic p21 was negatively correlated with the response to cisplatin based treatment. Conclusions: Cytoplasmic p21 is a novel biomarker of cisplatin resistance and it may represent a potential therapeutic target for ovarian tumors that are refractory to conventional treatment.Keywords
This publication has 44 references indexed in Scilit:
- Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancerJournal of Clinical Investigation, 2010
- Doxorubicin and Paclitaxel-Loaded Lipid-Based Nanoparticles Overcome Multidrug Resistance by Inhibiting P-Glycoprotein and Depleting ATPCancer Research, 2009
- Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cellsCarcinogenesis, 2008
- Molecular pathogenesis and therapeutic targets in epithelial ovarian cancerJournal of Cellular Biochemistry, 2007
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- Only Akt1 Is Required for Proliferation, while Akt2 Promotes Cell Cycle Exit through p21 BindingMolecular and Cellular Biology, 2006
- Signaling Intricacies Take Center Stage in Cancer CellsCancer Research, 2005
- Phosphorylation/Cytoplasmic Localization of p21Cip1/WAF1 Is Associated with HER2/ neu Overexpression and Provides a Novel Combination Predictor for Poor Prognosis in Breast Cancer PatientsClinical Cancer Research, 2004
- Aberrant Expression of Cyclin D1 Is Associated with Poor Prognosis in Early Stage Cervical Cancer of the UterusGynecologic Oncology, 2001
- Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.Journal of Clinical Investigation, 1991